骨髓增生异常综合征的免疫治疗：你可以逃避，但无法躲藏。

Immunotherapy of Myelodysplastic Syndrome: You Can Run, but You Can't Hide.

机构信息

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

出版信息

Clin Cancer Res. 2018 Mar 1;24(5):991-993. doi: 10.1158/1078-0432.CCR-17-2960. Epub 2017 Dec 28.

Abstract

The hypomethylating agent decitabine induces expression of the cancer/testis antigen NY-ESO-1 in the myeloid cells of patients with myelodysplastic syndrome (MDS). Patients with MDS treated with decitabine and an NY-ESO-1 vaccine developed NY-ESO-1-specific T-cell responses directed against their abnormal myeloid cells, raising hopes for combinatorial immunotherapy of this disease. .

摘要

去甲基化药物地西他滨可诱导骨髓增生异常综合征（MDS）患者髓系细胞中癌/睾丸抗原 NY-ESO-1 的表达。用地西他滨和 NY-ESO-1 疫苗治疗的 MDS 患者产生了针对其异常髓系细胞的 NY-ESO-1 特异性 T 细胞反应，为这种疾病的联合免疫治疗带来了希望。